What do systematic reviews say?

Subcutaneous insulin lispro vs intravenous regular insulin

• Subcutaneous rapid‐acting insulin analogues for diabetic ketoacidosis 2016 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 90 participants
  Very low

Subcutaneous insulin lispro vs intravenous regular insulin

The review found no eligible studies for this question.

• Subcutaneous rapid‐acting insulin analogues for diabetic ketoacidosis 2016 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Subcutaneous insulin aspart vs intravenous regular insulin

• Subcutaneous rapid‐acting insulin analogues for diabetic ketoacidosis 2016 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 45 participants
  Low

Subcutaneous insulin aspart vs intravenous regular insulin

Subcutaneous insulin aspart showed no clear difference in hypoglycaemic episodes (N) Mean hospital stay: 3‐5 days compared with intravenous regular insulin (low certainty).

• Subcutaneous rapid‐acting insulin analogues for diabetic ketoacidosis 2016 · Cochrane Headline outcomes only
  RR 1 [0.07, 14.55]
  1 study · 30 participants
  Low

Short‐acting insulin analogues vs regular human insulin

Short‐acting insulin analogues showed no clear difference in all‐cause mortality (N) compared with regular human insulin (moderate certainty).

• Short‐acting insulin analogues versus regular human insulin for adult, non‐pregnant persons with type 2 diabetes… 2018 · Cochrane Headline outcomes only
  Peto OR 1.66 [0.41, 6.64]
  6 studies · 2519 participants
  Moderate
• Short‐acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus 2016 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Short‐acting insulin analogues vs regular human insulin

• Short‐acting insulin analogues versus regular human insulin for adult, non‐pregnant persons with type 2 diabetes… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  6 studies · 2509 participants
  Low
• Short‐acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus 2016 · Cochrane Headline outcomes only
  OR 0.89 [0.71, 1.12]
  7 studies · 2459 participants
  Very low

Short‐acting insulin analogues vs regular human insulin

• Short‐acting insulin analogues versus regular human insulin for adult, non‐pregnant persons with type 2 diabetes… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  9 studies · 2608 participants
  Low
• Short‐acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus 2016 · Cochrane Headline outcomes only
  no estimate extracted
  9 studies · 2608 participants
  Low

Short‐acting insulin analogues vs regular human insulin

• Short‐acting insulin analogues versus regular human insulin for adult, non‐pregnant persons with type 2 diabetes… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 2 participants
  Very low
• Short‐acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus 2016 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Short‐acting insulin analogues vs regular human insulin

The review found no eligible studies for this question.

• Short‐acting insulin analogues versus regular human insulin for adult, non‐pregnant persons with type 2 diabetes… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Short‐acting insulin analogues vs regular human insulin

• Short‐acting insulin analogues versus regular human insulin for adult, non‐pregnant persons with type 2 diabetes… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 2667 participants
  Very low

Short‐acting insulin analogues vs regular human insulin

The review found no eligible studies for this question.

• Short‐acting insulin analogues versus regular human insulin for adult, non‐pregnant persons with type 2 diabetes… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Short‐acting insulin analogues vs regular human insulin

The review found no eligible studies for this question.

• Short‐acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus 2016 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Short‐acting insulin analogues vs regular human insulin

The review found no eligible studies for this question.

• Short‐acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus 2016 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Short‐acting insulin analogues vs regular human insulin

The review found no eligible studies for this question.

• Short‐acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus 2016 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: insulin detemir vs Insulin glargin (control)

The review found no eligible studies for this question.

• Insulin detemir versus insulin glargine for type 2 diabetes mellitus 2011 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: insulin detemir vs Insulin glargin (control)

The review found no eligible studies for this question.

• Insulin detemir versus insulin glargine for type 2 diabetes mellitus 2011 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: insulin detemir vs Insulin glargin (control)

• Insulin detemir versus insulin glargine for type 2 diabetes mellitus 2011 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 2250 participants
  Low

Summary of findings: insulin detemir vs Insulin glargin (control)

Insulin detemir (intervention) showed no clear difference in percentage of participants having at least one severe hypoglycaemic… compared with insulin glargin (control) (low certainty).

• Insulin detemir versus insulin glargine for type 2 diabetes mellitus 2011 · Cochrane Headline outcomes only
  RR 0.82 [0.51, 1.32]
  4 studies · 2252 participants
  Low

Summary of findings: insulin detemir vs Insulin glargin (control)

Insulin detemir (intervention) showed no clear difference in percentage of participants having at least one hypoglycaemic event compared with insulin glargin (control) (low certainty).

• Insulin detemir versus insulin glargine for type 2 diabetes mellitus 2011 · Cochrane Headline outcomes only
  RR 0.98 [0.92, 1.05]
  4 studies · 2252 participants
  Low

Summary of findings: insulin detemir vs Insulin glargin (control)

• Insulin detemir versus insulin glargine for type 2 diabetes mellitus 2011 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 2250 participants
  High